Vol 13, No 4 (2019)
Review paper
Published online: 2019-09-27
Drug selection in the treatment of breakthrough pain: how the pharmacokinetic profile of drugsis to be translated into clinical practice
Palliat Med Pract 2019;13(4):211-215.
Abstract
Breakthrough pain in cancer patients (BTP), also referred to as episodic or incident pain, occurs in a signif-icant proportion of patients with baseline pain (40–60%). It is characterized by rapid intensifying (within tens of seconds or a few minutes) and a strong intensity in the numerical rating scale always above 5 and a limited duration, usually up to about 60 minutes. The choice of the drug for the management of BTP in clinical practice should be based on a profound knowledge of pathophysiology of BTP and pharmacokinetic parameters of the drugs used.
References
- Dobrogowski J, Wordliczek J. Leczenie bólu. Wydawnictwo Lekarskie PZWL, Warszawa 2017.
- Malec-Milewska M, Woroń J. Kompendium leczenia bólu. Medical Education, Warszawa 2017.
- Hanna M, Żylicz Z. Cancer Pain. Springer, New York 2014.
- Novotna S, Valentova K, Fricova J, et al. ETHYFYL Study Group. A randomized, placebo-controlled study of a new sublingual formulation of fentanyl citrate (fentanyl ethypharm) for breakthrough pain in opioid-treated patients with cancer. Clin Ther. 2014; 36(3): 357–367.
- Woroń J. Chory na nowotwór. Interakcje analgetyków i leków stosowanych w terapii objawów współtowarzyszących. Medical Education, Warszawa 2019.
- Chisholm–Burns MA, Schwinghammer TL, Malone PM. Pharmacotherapy Principles & Practice. Mc Graw Hill Education, New York 2019.
- Rosenthal LD, Burchum JR. Pharmacotherapeutics for Advances Practice Providers. Elsevier, St. Louis 2018.
- DiPiro JT, Talbert LR, Yee GC. Pharmacotherapy, a Pathophysiologic Approach. Mc Graw Hill Education, New York 2017.
- Wirfs MJ. Prescribing Drug Therapy. Springer Publishing Company, New York 2019.
